EXCLUSIVE COmmercialization LICENSE AgreementLicense Agreement • May 7th, 2019 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Exclusive Commercialization License Agreement (the “Agreement”) is entered into as of January 22nd, 2019 (the “Effective Date”), by and between Rigel Pharmaceuticals, Inc., a Delaware company having an address at 1180 Veterans Blvd., South San Francisco, CA 94080, USA (“Rigel”) and Grifols Worldwide Operations Limited, an Irish company having an address at Grange Castle Business Park, Clondalkin, Dublin 22, Dublin, Ireland (“Grifols”). Rigel and Grifols may be referred to herein individually as a “Party” or collectively as the “Parties”.
